AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the T

Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus dataPreviously reported data show that bebtelovimab has broad and potent neutralization of all other known circulating SARS-CoV-2 variants of concernBebtelovimab binds to a rarely mutat...

Related Keywords

United Kingdom ,Vancouver ,British Columbia ,Canada ,British ,Jessica Yingling ,Eli Lilly ,Carl Hansen ,Neil Berkley ,Vaccine Research Center ,Company Lilly ,Abcellera Biologics Inc ,Drug Administration ,Exchange Commission ,National Institutes For Allergy ,Defense Advanced Research Projects Agency ,Business Development ,Emergency Use Authorization ,Use Authorization ,National Institutes ,Infectious Diseases ,Pandemic Prevention Platform ,Private Securities Litigation Reform Act ,Financial Condition ,Abcellera Biologics ,Melanie Solomon ,